Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | NR1D1 | P20393 | 4/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14798981 | 0.83 | S1PR1 (0.36) | NR1D1S1PR1NR1H3TSHRMEN1 | |
| SCHEMBL14798320 | 0.82 | RXRA (0.41) | NR1H3 | |
| SCHEMBL14839652 | 0.79 | PAX8 (0.44) | LTA4HNR1H3CTSLCTSBCTSS | |
| SCHEMBL14798408 | 0.76 | ADRB2 (0.39) | NR1H3ALDH1A1 | |
| SCHEMBL4743834 | 0.76 | LTA4H (0.46) | LTA4HNR1D1S1PR1ALDH1A1 | |
| SCHEMBL14805294 | 0.75 | SMN1; SMN2 (0.38) | LTA4HMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL28163472 | 0.73 | LTA4H (0.41) | LTA4HMEN1ALDH1A1KMT2ACD274 | |
| SCHEMBL14798480 | 0.72 | ALDH1A1 (0.40) | LTA4HS1PR1MEN1ALDH1A1KMT2A | |
| SCHEMBL20339008 | 0.72 | CTSL (0.48) | CTSLCTSBCTSSTSHRAKT1 | |
| Hydrochloric Acid SCHEMBL27968630 | 0.72 | LTA4H (0.40) | LTA4HTSHRMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760838-B1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARM SPA (IT) | 2017-05-10 | — | — | EP | disclosed |
| US-9265768-B2 | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-02-23 | — | — | US | disclosed |
| EP-2760838-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2014-08-06 | — | — | EP | disclosed |
| US-20140142074-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-05-22 | — | — | US | disclosed |
| WO-2013045280-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079313-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079313-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE3A | LTA4H 160/4885NR1D1 4124/4885S1PR1 391/4885 |
| US-20140142074-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE3A | LTA4H 160/4885NR1D1 4124/4885S1PR1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.